Danish Headache Center clinical trials
Danish Headache Center is the lead sponsor of 10 current clinical trials in our Denmark register. 6 are recruiting patients now. The most common phase is Not applicable. The drugs named most often in its trials are Adrenomedullin and Amylin. The most-studied condition is Posttraumatic Headache.
ClinicalTrials.gov trials by status
Trials by phase
Clinical trials sponsored by Danish Headache Center
10 on ClinicalTrials.gov| Study | Phase | Status | Start | Registers |
|---|---|---|---|---|
|
Hypersensitivity to Adrenomedullin in Post-Traumatic Headache
NCT07059546 · ClinicalTrials.gov ↗ · Posttraumatic Headache
Drug: Adrenomedullin |
Not applicable | Recruiting | 2025-08 | Denmark |
|
Selective Activation of the Adrenomedullin Receptors in Migraine
NCT07451769 · ClinicalTrials.gov ↗ · Migraine, Brain Diseases, Central Nervous System Diseases
Drug: Adrenomedullin |
Not applicable | Recruiting | 2026-03 | Denmark |
|
Induction of Migraine Attacks With Aura Using Calcitonin Gene-Related Peptide
NCT07021859 · ClinicalTrials.gov ↗ · Migraine Aura, Migraine With Aura
|
Not applicable | Recruiting | 2025-06 | Denmark |
|
Diagnostic and Prognostic Biomarkers of Idiopathic Intracranial Hypertension
NCT04032379 · ClinicalTrials.gov ↗ · Benign Intracranial Hypertension
|
Observational | Recruiting | 2018-02 | Denmark |
|
Substance P-Induced Migraine Attacks Without Aura
NCT06959004 · ClinicalTrials.gov ↗ · Migraine
|
Not applicable | Recruiting | 2025-05 | Denmark |
|
Safety and Efficacy of Botulinum Toxin A in Patients With Posttraumatic Headache
NCT06839118 · ClinicalTrials.gov ↗ · Posttraumatic Headache
|
Phase 3 | Recruiting | 2025-01 | Denmark |
|
Hypersensitivity to Amylin in Post-Traumatic Headache
NCT07340775 · ClinicalTrials.gov ↗ · Headache Disorders, Secondary, Brain Diseases, Headache Disorders
Drug: Amylin |
Not applicable | Not yet open | 2026-02 | Denmark |
|
Amylin-Induced Migraine Attacks Without Aura
NCT07340788 · ClinicalTrials.gov ↗ · Headache Disorders, Primary, Headache Disorders, Brain Diseases
Drug: Amylin |
Not applicable | Not yet open | 2026-02 | Denmark |
|
Pathophysiology and Treatment of Cerebrospinal Hypotension Exploration Study
NCT06805591 · ClinicalTrials.gov ↗ · Spontaneous Intracranial Hypotension, Intracranial Hypotension, Post-Lumbar Puncture Headache
|
Observational | By invitation | 2024-12 | Denmark |
|
Muscle Function and Tenderness Differences in Headache Patients
NCT06859463 · ClinicalTrials.gov ↗ · Migraine, Tension Headache, Posttraumatic Headache
|
Observational | By invitation | 2025-02 | Denmark |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Titles and statuses are copied from the registry as published.
Drugs in Danish Headache Center trials
2 compoundsDrugs and biologicals named as interventions in these trials, with the number of this sponsor's trials that name each one. Placebos and generic comparators are excluded.
Conditions in Danish Headache Center trials
16 conditionsBy trial register
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in Denmark | 10 | 6 |
A trial with sites in more than one country appears in each of those registers.
Questions about Danish Headache Center trials
How many clinical trials does Danish Headache Center sponsor?
Danish Headache Center is the lead sponsor of 10 current trials on ClinicalTrials.gov in our Denmark register, as of the registry sync on 12 November 2026. Completed and withdrawn studies are not counted.
Are Danish Headache Center trials recruiting?
Yes. 6 of its 10 ClinicalTrials.gov trials are recruiting. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Which drugs is Danish Headache Center testing?
Its current trials name 2 drugs and biologicals as interventions. The most frequent are Adrenomedullin (2) and Amylin (2). The number in brackets is how many of its trials name each drug.
Where does this information come from?
Every trial, status, phase and condition on this page is copied from public ClinicalTrials.gov and EU CTIS records by a daily sync, grouped by the sponsor name each registry records. It says nothing about the organisation beyond its registered trials, and it is not medical advice.
How this page is built
Everything on this page is copied from public registry records — it is not written from memory, and nothing here describes the organisation beyond its registered trials. Each trial links to its own record so you can check it yourself.
- ClinicalTrials.gov (U.S. National Library of Medicine) ↗ Trial IDs, titles, lead sponsor, phase, overall status, start date, conditions and intervention names
- EU Clinical Trials Information System (CTIS) ↗ EU trial numbers, titles, sponsor, phase, status, therapeutic area and member-state countries
This page is built automatically: a daily sync job reads the registry records behind our trial registers and groups every current trial by its lead sponsor name, ignoring legal-form suffixes such as Inc. or Ltd. A small, hand-checked list joins the same organisation's different registry names (for example its EU legal entity). There is no AI drafting and no per-sponsor editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The the registries data on this page was last retrieved on 12 Nov 2026. How every register is built: methodology · fixes we have made: corrections log.